Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112346 · ClinicalTrials.gov registry record · Phase 2
Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00112346 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 120 participants.
The verdict
NCT00112346, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The primary purpose of this study is to estimate the number of patients with non-small cell lung cancer whose tumor responds to the treatments given in this study.
Interventions
- DRUG Cetuximab + platinum + gemcitabine
- DRUG Platinum + Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00112346
The ClinicalTrials.gov registry entry for NCT00112346 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetuximab + platinum + gemcitabine is the first listed.
NCT00112346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00112346 about?
NCT00112346 is a clinical study titled "Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer". The primary purpose of this study is to estimate the number of patients with non-small cell lung cancer whose tumor responds to the treatments given in this study.
What is the current status of trial NCT00112346?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2005-01. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00112346?
The interventions under investigation include: Cetuximab + platinum + gemcitabine (DRUG), Platinum + Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00112346?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.